Fulgent Genetics Reports Second Quarter 2019 Financial Results
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: GlobeNewswire
Second Quarter 2019 Results: Record billable tests of 16,369, growing 187% year over yearRecord revenue of $8.4 million, growing 56% year over yearGross Margin improves more than 12 percentage points sequentially; cost per test improves by 44% sequentiallyPosts profit; GAAP income of $331,000, or $0.02 per shareNon-GAAP income of $1.2 million, or $0.06 per shareCash flow from operations of positive $675,000Adjusted EBITDA of $1.5 million TEMPLE CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced financial results for its second quarter ended June 30, 2019. Second quarter revenue was $8.4 million, an increase of 56% year over year from $5.4 million in the second quarter of 2018. GAAP income for the second quarter of 2019 was $331,000, or $0.02 per share, and non-GAAP income was $1.2 million, or $0.06 per share. Adjusted EBITDA was $1.5 million in the second quarter of 2019, an increase of 1,447% yea
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Oncology Specimen Provider Reference Medicine Announces Launch of Characterized Specimens, Enabling Increased Speed and Efficiency for Assay DevelopersPR Web
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) had its price target lowered by analysts at Piper Sandler from $26.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
FLGT
Earnings
- 11/8/24 - Beat
FLGT
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form 8-K
- 11/5/24 - Form SC
- FLGT's page on the SEC website